Opens in a new tab or window Upadacitinib combined with topical corticosteroids led to rapid and lasting relief from atopic dermatitis (AD) symptoms compared with placebo. Researchers also ...
AbbVie said the study is the first head-to-head trial in atopic dermatitis assessing upadacitinib at a starting ... moderate-to-severe atopic dermatitis (AD) who had an inadequate response to ...
AbbVie’s attempts to diversify beyond Humira have been boosted as its investigational drug upadacitinib has been granted Priority Review by the FDA for moderate to severe rheumatoid arthritis (RA).